Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relief of acute migraine attacks with an analgesic/antihistamine combination containing paracetamol, codeine phosphate, doxylamine succinate and caffeine (Mersyndol) compared with that achieved with a placebo has been studied in a double-blind, crossover trial. Mersyndol emerged as significantly better than placebo in the complete relief of migraine pain, and was clearly superior to placebo in partially relieving the pain of migraine. These results suggest that it could be a useful alternative to ergotamine, and a comparative trial with ergotamine is suggested. Side effects with this combination were fairly common but mild, and consisted mainly of drowsiness caused by the antihistamine component.
 ...
PMID:Treatment of migraine attacks with an analgesic combination (Mersyndol). 78 38

Zinc oxide-eugenol cements are considerably better tolerated by tissue than other dental materials. As they alleviate pain and are bacteriostatic and antiseptic, they are well tolerated by patients. The cements are good insulators and possess better sealing properties than zinc phosphate cements. Because of their poor mechanic properties, the conventional zinc oxide-eugenol cements are mainly used as temporary fixing contents and filling materials, for gingival dressings and together with filling materials as impression materials. Recently, reinforced zinc oxide-eugenol cements and cements containing ethoxy benzoic acid (EBA) have been developed. These new cements have considerably better mechanic properties and are therefore used for cement bases, indirect capping, long-term temporary fillings and in selected cases as definite fixing cements.
 ...
PMID:[Zinc oxide-eugenol as dental material (1)]. 79 30

In 34 patients with coronary atherosclerosis a pacing test was performed with measurement of the lactate, glucose, potassium and inorganic phosphate coronary arterio-venous differences. Eighteen of these 34 patients felt no pain during the pacing test. In this group of asymptomatic patients, there was no significant change of the lactate, glucose, potassium and inorganic phosphate myocardial extraction. In the 16 patients who felt an anginal pain during the pacing test, there was a significant myocardial production of lactate, but the myocardial loss of potassium and inorganic phosphate was not continuously statistically significant. Myocardial extraction of glucose during the pacing-induced angina did not increase. Although, in some patients, both the potassium and the inorganic phosphate might be used to assess a condition of myocardial ischaemia, the lactate remains the best metabolic criterion for pacing-induced ischaemia.
 ...
PMID:[Values of glucose, potassium and inorganic phosphate as metabolic indicators of myocardial ischemia in humans]. 80 87

A disabling osteomalacic syndrome seen only during regular hemodialysis is described. Its features include skeletal fractures, pain, suppression of pre-existing hyperparathyroidism, and failure to improve with any of the vitamin-D metabolites. Phosphate depletion may be an important etiological factor but this could not explain all cases. A trial with phosphate-enriched dialysate and 1alphaOHD3 resulted in sustained clinical improvement in 54% of the patients and healing of fractures in 33%. Other etiological factors independent of 1,25(OH)2D3 deficiency and phosphate depletion must be considered. Current, indirect evidence suggests that accumulation of water toxins including aluminium may be important.
 ...
PMID:The need and use of a phosphate-enriched dialysate during regular hemodialysis. 91 Mar 60

(1) The isolated rabbit ear was perfused via its artery and the venous outflow superfused a PGE-sensitive rat stomach strip or a PGF-sensitive rat colon. (2) Injection of bradykinin intra-arterially into the ear produced a larger contraction of the rat stomach strip than the application of the same dose of bradykinin directly to the superfused muscle. (3) This difference is explained as a release of PGE-like material by bradykinin since indomethacin (infused i.a. into the ear) reduced the effect of the i.a. applied bradykinin. (4) PGF-like material could not be detected in the venous effluent. (5) ACh released only minimal amounts of PGE-like substance. (6) CONCLUSION: The amount of PGE-like material released by bradykinin is large enough to sensitize the paravascular pain receptors in the rabbit ear for the attack of bradykinin. Therefore, inhibition of PG-synthesis (i.e. by indomethacin) or inhibition of the sensitizing action of E-type PGs (i.e. by polyphloretin phosphate) reduces the pain producing effect of bradykinin. Since ACh releases only minimal amounts of E-type PGs, its effect is reduced only to a minimal extent by indomethacin or polyphloretin phosphate.
 ...
PMID:Release of prostaglandins from the isolated perfused rabbit ear by bradykinin and acetylcholine. 97 Feb 94

(1) The method of the isolated perfused rabbit ear connected to the body by its nerve only was used to investigate the influence of the prostaglandin-antagonist polyphloretin phosphate (PPP) on the algesic effect of bradykinin (B) and acetylcholine (ACh). (2) Intra-arterial injections of B and ACh into the ear elicit a reflex fall in systemic blood pressure of the anaesthetized animal. PPP reduces this effects of B in proportion to the dose. The effect of ACh is reduced only to a small extent and only under higher concentrations of PPP than those necessary for inhibiting the effect of B. (3) Prostaglandin E1 (PGE1), when infused i.a. into the ear, enhances the effect of B and ACh by a sensitizing action on the perivascular pain receptors. PPP reduces or totally abolishes the PGE1-induced enhancement of the effect of B and ACh. (4) It is concluded that PPP reduces the effect of B mainly by inhibiting directly the pain enhancing action of the endogenously released PGs of the E-type. The effect of ACh is reduced only in the high concentration of PPP to a small extent probably by inhibiting the ACh-action rather than the sensitizing action of the only minimal released amounts of PGs. The PG-antagonizing action of PPP is further proven by the fact that during an additional infusion of PGE1 the enhanced effects of both B as well as ACh are reduced or abolished by PPP.
 ...
PMID:Polyphloretin phosphate reduces the algesic action of bradykinin by interfering with E-type prostaglandins. 97 Feb 95

Severe proximal myopathy associated with hypophosphatemia developed in three patients with chronic renal failure who had been treated with aluminum hydroxide gel. The syndrome was characterized by severe pain, muscular stiffness, and weakness. The illness was originally misdiagnosed both as uremic myopathy and as an exacerbation of rheumatoid arthritis. In one patient, the correct diagnosis was made when symptomatic relief corresponded to the rise of serum phosphate levels. Discontinuation of antacid therapy was followed by gradual recovery. Oral sodium phosphate brought prompt alleviation of muscular pain and stiffness.
 ...
PMID:Proximal myopathy caused by latrogenic phosphate depletion. 98 96

Pacing-induced myocardial ischemia in 18 patients resulted in an increase of coronary sinus hypoxanthine levels from 1.20 +/- 0.18 micron during control to 2.41 +/- 0.52 micron (p less than 0.025) during pain. In addition, early lactate production occurred frequently before angina was noted. Neither hypoxanthine nor lactate levels changed in seven nonanginal patients, nor were significant alterations in potassium, inorganic phosphate, glucose, or oxygen saturation found in all patients. Myocardial hypoxanthine production seems a useful indicator of ischemia in the human heart.
 ...
PMID:Changes in purine nucleoside content in human myocardial efflux during pacing-induced ischemia. 103 94

Reports received from 32 dentists on the effect of a complex mixture of calcium sucrose phosphate and calcium orthophosphate used as a gel, toothpaste, or slurry in relieving pain in hypersensitive dentine show, in 137 patients, complete relief in 112. It was found that in 54 patients the prior use of stannous fluoride prophylactic paste was beneficial.
 ...
PMID:Dentine hypersensitivity. 106 73

Thirty-two patients with stage D carcinoma of the prostate were treated with oral estramustine phosphate at a dose of 15 mg/kg/day from 3 to 15 months. Objective remissions, reduction of greater than 50 percent of measurable lesions such as soft tissue masses, lymph nodes, and prostatic masses, were seen in seven of 32 patients (22 percent response rate). Subjective response, ie, relief of pain, weight gain, sense of well being, snd improved performance status, occurred in all objective responders and in seven other patients with stable disease (15 of 32 patients = 47 percent). No hematologic, hepatic, or renal toxic effects were observed. Transient nausea occurred early in one half of the patients and nausea and vomiting was dose limiting in only two patients. Oral estramustine phosphate is well tolerated and worthy of further clinical use.
 ...
PMID:Oral estramustine phosphate (NSC-89199) in the treatment of advanced (stage D) carcinoma of the prostate. 109 69


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>